TAK 960

Drug Profile

TAK 960

Alternative Names: TAK-960

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Millennium
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 04 Feb 2013 Discontinued - Phase-I for Solid tumours in USA (PO)
  • 04 Feb 2013 Discontinued - Preclinical for Acute myeloid leukaemia in USA (unspecified route)
  • 01 Jan 2013 Takeda completes a phase I trial in Solid tumours (late stage disease) in USA (NCT01179399)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top